Novoprotein(SH:688137)2024-04-28 07:46Financial Performance - The company's revenue for Q1 2024 was CNY 26,087,054.66, representing a decrease of 39.34% compared to the same period last year[9]. - The net profit attributable to shareholders was a loss of CNY 2,630,474.68, a decline of 123.61% year-over-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of CNY 11,706,041.48, down 273.62% from the previous year[9]. - Total operating revenue for Q1 2024 was CNY 26,087,054.66, a decrease of 39.2% compared to CNY 43,002,533.69 in Q1 2023[19]. - Net profit for Q1 2024 was a loss of CNY 2,630,474.68, compared to a profit of CNY 11,141,255.79 in Q1 2023[20]. - In Q1 2024, the company reported a total comprehensive income of -2,647,658.46 CNY, a significant decrease from 11,137,303.03 CNY in Q1 2023[21]. - The basic and diluted earnings per share for Q1 2024 were both -0.04 CNY, compared to 0.16 CNY in Q1 2023[21]. Cash Flow and Liquidity - The net cash flow from operating activities was CNY 7,558,148.81, a decline of 68.17% compared to the same period last year[8]. - Cash inflows from operating activities totaled 56,919,605.96 CNY in Q1 2024, down 26.8% from 77,756,134.69 CNY in Q1 2023[22]. - The total cash outflow from operating activities was 49,361,457.15 CNY, compared to 54,012,021.66 CNY in the previous year[24]. - The company’s cash and cash equivalents at the end of Q1 2024 were 1,392,721,519.76 CNY, compared to 1,485,658,036.01 CNY at the end of Q1 2023[25]. - The company paid 28,597,863.67 CNY to employees in Q1 2024, a slight increase from 27,768,702.82 CNY in Q1 2023[24]. - The company’s cash and cash equivalents as of March 31, 2024, amount to ¥1,393,411,953.22, an increase from ¥863,702,581.67 on December 31, 2023[15]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,310,126,014.98, reflecting a slight increase of 0.49% from the end of the previous year[5]. - Total assets as of Q1 2024 amounted to CNY 2,310,126,014.98, an increase from CNY 2,298,915,220.36 in the previous year[18]. - Total liabilities for Q1 2024 were CNY 121,058,435.51, up from CNY 110,425,722.31 in Q1 2023[17]. - The company's total equity as of Q1 2024 was CNY 2,189,067,579.47, slightly up from CNY 2,188,489,498.05 in the previous year[18]. Research and Development - Research and development expenses totaled CNY 11,000,774.78, accounting for 42.17% of revenue, an increase of 16.57 percentage points year-over-year[5]. - Research and development expenses for Q1 2024 were CNY 11,000,774.78, slightly down from CNY 11,008,017.25 in Q1 2023[20]. - The company is actively pursuing new technologies and products in mRNA vaccines, biopharmaceuticals, and life sciences research[9]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,641[11]. - The largest shareholder, Shanghai Xinbainuo Biotechnology Co., Ltd., holds 30,355,000 shares, accounting for 43.26% of total shares[11]. - The second-largest shareholder, Wujiang Dongyun Venture Capital Co., Ltd., holds 10,120,000 shares, representing 14.42% of total shares[11]. - The total number of shares held by the top ten shareholders includes significant stakes from various investment partnerships[12]. - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[13]. - The company has not disclosed any related party transactions among the top shareholders[13]. - The company’s actual controller is Zhu Huaxing, who indirectly holds shares through several investment entities[13]. Operational Challenges - The company faced challenges due to a phase adjustment in the domestic biopharmaceutical market and a slowdown in conventional business growth[9]. - The report does not indicate any significant operational changes or new strategies during the reporting period[14]. Marketing and Sales - The company expanded its marketing team and increased sales expenses to enhance business development and brand building[9]. - The company reported a significant increase in sales expenses, which reached CNY 11,402,508.31, compared to CNY 8,499,041.02 in Q1 2023[20].